Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.41 |
| ▸ | FLT1 | P17948 | 2/20 | 0.41 |
| ▸ | FLT4 | P35916 | 2/20 | 0.41 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 7/20 | 0.41 |
| ▸ | JAK2 | O60674 | 4/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21544 | 0.87 | JAK2 (0.46) | KDRFLT1FLT4KARS1SYK | |
| SCHEMBL20010 | 0.85 | KDR (0.52) | KDRFLT1FLT4SYKJAK2 | |
| SCHEMBL15207482 | 0.84 | SYK (0.40) | KDRFLT1FLT4SYKJAK2 | |
| SCHEMBL21230 | 0.84 | KDR (0.43) | KDRFLT1FLT4SYKJAK2 | |
| SCHEMBL15206747 | 0.84 | NOS3 (0.39) | KDRFLT1FLT4SYKJAK2 | |
| SCHEMBL19518 | 0.83 | JAK2 (0.56) | SYKJAK2PTK2EIF2AK4 | |
| SCHEMBL21149 | 0.82 | SYK (0.46) | KDRFLT1FLT4SYK | |
| SCHEMBL20253 | 0.82 | KDR (0.54) | KDRFLT1FLT4SYKJAK2 | |
| SCHEMBL20465 | 0.81 | KDR (0.43) | KDRFLT1FLT4SYKJAK2 | |
| SCHEMBL25496 | 0.80 | JAK2 (0.54) | JAK2PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609098-B1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-07-13 | — | — | EP | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-9023851-B2 | Triazolopyrazine derivatives | MERCK PATENT GMBH (DE) | 2015-05-05 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225568-A1 | TRIAZOLOPYRAZINE DERIVATIVES | SYK, IRAK1, ZAP70 | KDR 242/4885FLT1 47/4885FLT4 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.